A site where you can find recommended contractors for non-clinical testing|effical " Non-Clinical CROs and Agencies " Cyagen

Cyagen

Cyagen is a contract research organization (CRO) providing non-clinical research services in drug discovery and regenerative medicine. The company delivers highly reproducible data through integrated services ranging from custom mouse model generation to in vitro and in vivo evaluations.
As Cyagen primarily operates as a research institution conducting studies in-house, it does not function as an intermediary agency.

Features of Cyagen’s Contract Services for Non-Clinical Studies

Integrated In Vivo and In Vitro Platforms for Comprehensive Efficacy Evaluation

Cyagen supports both in vivo efficacy studies using immunodeficient and humanized mouse models and in vitro evaluations utilizing cell-based assay systems.
The company leverages proprietary NKG mouse models alongside extensive oncology and immune reconstitution models to precisely evaluate the therapeutic efficacy of cell-based therapies, including CAR-T and NK cell therapies.
Multifaceted endpoints—including cytotoxic activity, cytokine secretion, ADCC, and ADCP—support the generation of highly reproducible preclinical datasets.

One-Stop Platform for Rapid Delivery of High-Quality Mouse Model

Cyagen provides customized genetically engineered mouse models—including knockout, knock-in, and transgenic lines—within accelerated timelines.
Using proprietary technologies such as TurboKnockout® and CRISPR-Pro, founder mice can be generated in as little as three to six months.
Cyagen maintains a fully integrated workflow covering genetic engineering, breeding, and quality validation, enabling cost-effective model development that accelerates drug discovery programs.

AI-Integrated Gene Therapy Development Platform

Cyagen offers CRO services integrating artificial intelligence with experimental validation for gene therapy development.
By leveraging its Rare Disease Data Center (RDDC) and deep learning technologies, Cyagen supports workflows from pathogenic mutation identification to AAV vector design and in vivo validation.
The combination of AI-driven predictive analysis and validation using custom cell and animal models streamlines early discovery through preclinical development, contributing to accelerated R&D timelines and improved success rates.

Example of Disease Models Available at Cyagen

Custom Mouse Models for Human Disease Research

Cyagen maintains a broad portfolio of genetically engineered mouse models supporting drug discovery and disease research.
The company develops knockout, knock-in, and humanized mouse models using proprietary technologies, including TurboKnockout® and CRISPR-Pro, enabling rapid and highly accurate disease model generation.

Transgenic Mouse Models Using Gene Transfer Technologies

Transgenic mouse models replicate specific disease phenotypes or biological functions through random integration of exogenous genes.
Cyagen provides end-to-end services, including vector design, pronuclear microinjection, and screening, to establish multiple founder lines with varying expression profiles, allowing selection based on specific research objectives.

Cyagen Non-Clinical Case Studies

Integrated Efficacy Evaluation from Cell-Based Assays to Animal Models

Cyagen evaluates therapeutic efficacy of cell therapy candidates—including CAR-T and CAR-NK therapies—through both in vitro and in vivo platforms. In cell-based assays, immune cell activation is assessed through cytotoxicity assays against target cells and quantification of IFN-γ secretion.
In tumor xenograft studies using C-NKG mouse models, treated groups demonstrated tumor growth inhibition and prolonged survival.
These integrated experimental platforms support confirmation of therapeutic reproducibility and safety at the preclinical stage.

Saiyajen case study images
Reference: Cyagen's official website (https://www.cyagen.jp/business/products/cell-therapy-solutions/in-vitro-evaluation.html)
Saiyajen case study images
Reference: Cyagen's official website (https://www.cyagen.jp/business/products/cell-therapy-solutions/in-vitro-evaluation.html)
Saiyajen case study images
Reference: Cyagen's official website (https://www.cyagen.jp/business/products/cell-therapy-solutions/in-vivo-evaluation.html)
Saiyajen case study images
Reference: Cyagen's official website (https://www.cyagen.jp/business/products/cell-therapy-solutions/in-vivo-evaluation.html)

Cyagen Company Information

Address 2255 Martin Avenue, Suite E, Santa Clara, CA 95050-2709, USA
Tel +1 408-969-0306
Website https://www.cyagen.jp/
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
  • SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
  • From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.

  • With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc.
(Labcorp Drug Development)
Labcorp Holdings Inc.
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
  • Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
  • The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
  • Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
  • PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
  • With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.

  • The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

By region
list of animal models
Expertise & Track Record
3 Recommended Contract Non-Clinical Testing Services